Akebia Therapeutics Inc.
AKBA
Market Cap$795.79M
Close$
$-2.20
159.7% downside
Current Fair Value
159.7% downsideOvervalued by 159.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $795.79 Million |
|---|---|
| Enterprise Value | $737.80 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.33 |
| Beta | 0.88 |
| Outstanding Shares | 235,497,720 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -15.75 |
|---|---|
| PEG | 11.75 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.03 |
| Enterprise Value to EBIT | -31.21 |
| Enterprise Value to Net Income | -17 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 2.25 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Akebia Therapeutics Inc.
CEO: John Butler